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Background: Environmental exposure chambers have been used to expose subjects to aeroallergens to
investigate the efﬁcacy of prophylactic treatment with symptomatic agents in Japan. We ﬁrst examined
the therapeutic effect of bilastine (BIL), a novel non-sedative second-generation H1-antihistamine, in
subjects with Japanese cedar pollinosis using an artiﬁcial exposure chamber (OHIO Chamber).
Methods: This was a randomized, double-blind, four-way crossover, placebo- and active-controlled phase
II study (trial registration number JapicCTI-132213). Subjects were exposed to cedar pollen (8000 grains/
m3) for 2 h on Day 1 and 4 h each on Day 1 and 2. BIL 10 or 20 mg, placebo, or fexofenadine hydro-
chloride (FEX) 60 mg was administered orally 1 h after the start of pollen exposure on Day 1. Placebo or
FEX was administered 12 h after the ﬁrst dosing. The primary efﬁcacy endpoint was the sum of total
nasal symptom score (TNSS) from 0 to 3 h after the Day 1 dosing.
Results: We enrolled 136 subjects and the sum of TNSS on Day 1 of the three active treatments was
signiﬁcantly lower than that of placebo and was maintained up to 26 h after the ﬁrst dosing (Day 2). The
sum of TNSS or sneezing score on Day 1 after BIL 20 mg was more signiﬁcantly decreased than after FEX.
Moreover, BIL showed a faster onset of action than FEX.
Conclusions: We demonstrated the efﬁcacy, rapid onset, and long duration of action of BIL in subjects
with Japanese cedar pollinosis exposed to cedar pollen using the OHIO Chamber.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ngology, Futaba Clinic, 20
ashiguchi).
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Japanese cedar (JC) pollinosis is a seasonal allergic rhinitis (SAR),
which is unique to Japan, and the causative allergen (JC pollen) is
dispersed usually between February and April although the pollen
count varies every year. According to a recent epidemiologicalvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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26.5% in 2008.1
Environmental exposure chambers (EECs) have been used to
assess the efﬁcacy and onset and duration of action of anti-allergic
drugs in subjects with seasonal or perennial allergic rhinitis
exposed to aeroallergens.2,3 Efﬁcacy assessment using the EEC is
approved and accepted by the US Food and Drug Administration
(FDA),4 the European Medicines Agency5 and the Japanese Phar-
maceutical and Medical Devices Agency (PMDA). While there is no
universally adopted guideline on the clinical development of new
drugs for allergic rhinitis, the PMDA has accepted clinical studies
using EEC for the new drug application.
We built an artiﬁcial allergen exposure chamber (OHIO Cham-
ber) in the center of Tokyo in September, 2008,6 and have used it to
conduct basic and clinical studies in subjects with JC pollinosis
exposed to JC pollen.6e10 There are three allergen exposure facilities
in Japan (Wakayama,11 Tokyo,6 Chiba12), which currently conduct
clinical studies in JC pollinosis. In addition, to the best of our
knowledge, most of the studies conducted assessed prophylactic
treatments, except for two clinical studies that evaluated the
therapeutic effect of the H1-antihistamine agents, cetirizine hy-
drochloride11 and bepotastine besilate.13 Alternatively, numerous
overseas clinical studies using the EEC have been conducted to
evaluate the efﬁcacy, as well as onset and duration of treatment
with study drugs.2,3,14
Bilastine (BIL) is a novel non-sedating second-generation H1-
antihistamine, which has been approved for the symptomatic
treatment of allergic rhinitis and urticaria in numerous countries
(Europe, Central and South America, and Africa), but not Japan.15
The overseas clinical studies in subjects with SAR demonstrated
that BIL 20 mg administered once daily for 2 weeks exerted an
efﬁcacy that was comparable to that of cetirizine16 and
desloratadine.17
We conducted a single-center, randomized, double-blind, four-
way crossover, placebo-, and active-controlled phase II study to
evaluate the efﬁcacy of therapeutic treatment with BIL in Japanese
subjects with cedar pollinosis by using the OHIO Chamber.Methods
Subjects
The study subjects were 20e60-year-old patients with JC
pollinosis presenting with a2-year history of symptoms, who had
received medical treatment including oral H1-antihistamines dur-
ing the JC pollen season, and had a positive CAP-
radioallergosorbent test (RAST) class 2 of serum speciﬁc immu-
noglobulin E (IgE) to JC pollen. In addition, subjects meeting any of
the following conditions were excluded:
 Diagnosedwith or had a history of severe systemic disease (such
as liver, renal, blood, and cardiac disease, neurological disorder,
or malignant tumor).
 Nasal disorder, which may affect the efﬁcacy of the study drugs
(e.g., vasomotor, drug-induced, and hypertrophic rhinitis;
deviated nasal septum, sinusitis, and nasal polyp)
 Underwent nasal surgery to improve nasal symptoms or un-
derwent speciﬁc or nonspeciﬁc immunotherapy within 5 years
before the start of the study.
 Used any of the following drugs before the start of the study:
steroid injection (180 days), other study drug (90 days), oral or
topical steroid, drugs with P-glycoprotein (P-gp) inhibitoryaction (30 days), antihistamines, or leukotriene receptor an-
tagonists (14 days).
 Pregnant or lactating women, and women who wish to become
pregnant during the study period.
 Symptoms of upper respiratory infections within 14 days prior
to ﬁrst dosing.
 Concurrent bronchial asthma.
 History of allergic reaction to FEX.
 Determined ineligible to participate in the study by the
investigator.Study design
This study was a phase II study, performed outside of the JC
pollen season in subjects with asymptomatic JC pollinosis, using
the OHIO Chamber as described elsewhere.6e8 The study
comprised three periods, the screening, treatment, and follow-up
periods. The screening period was conducted in a single-blind
manner for subjects while the treatment period was a random-
ized, double-blind, placebo- and active-controlled, four-way
crossover study (Fig. 1A).
After obtaining informed consent from the subjects, those who
met the inclusion criteria and did not violate the exclusion criteria
were asked to re-visit the institution during the screening period to
undergo exposure to JC pollen (8000 grains/m3) for 4 h. The sub-
jects were orally administered the placebo 1 h after the start of
exposure to assess the nasal symptom score and exclude any pla-
cebo effect.
The total nasal symptom score (TNSS) was used as an index to
evaluate the subjects for eligibility to transition from the screening
to the treatment period. The TNSS represents the scores of the
subjective symptoms of rhinorrhea, sneezing, nasal obstruction,
and nasal itching assessed on a 5-point scale (0e4). The inclusion
criteria were set as follows:
 TNSS  2, 1 h after the start of pollen exposure (maximum 16).
 A sum of TNSS  36 at speciﬁc time points after the placebo
administration to 3 h (12 time points, maximum 192).
The exclusion criteria were set as follows:
 Total amount of rhinorrhea 2 g during pollen exposure (4 h).
 A decrease of 2 in TNSS from baseline (just before placebo
administration) at any time point during the 1 h after the pla-
cebo administration.
Subjects deemed eligible during the screening exposure were
rolled over to the treatment period, which was comprised of four
groups. The subjects were randomly assigned to one of the four
groups and the treatment period consisted of four 3-day periods
that ran consecutively (Fig. 1B). A washout period of 10 days was
employed.
On Day 1, the subjects were exposed to pollen for 2 h as the
priming exposure. Then, subjects with a mean TNSS  1 from 1 to
2 h after the start of exposure proceeded to Day 1, during which
they were exposed to pollen for 4 h (the following day of the
priming exposure). This was followed by the administration of the
ﬁrst study drug 1 h after the start of exposure, and then the sec-
ondary drug was administered 12 h after the ﬁrst dosing. On Day 2,
the subjects returned to the OHIO Chamber 22 h after the ﬁrst
dosing and were further exposed to pollen for 4 h. When the
subjects could not tolerate the nasal or ocular symptoms after
Fig. 1. Study design and schedule of Japanese cedar (JC) pollen exposure. (A) Overall study design was comprised of three periods (screening, treatment, and follow-up). Treatment
period was composed of four periods. (B) Each period ran for 3 consecutive days (Day 1, 1, and 2). EEC, environmental exposure chambers; FU, follow up; IC, informed consent; R,
randomized; WO, washout.
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were allowed to use an a2 agonist nasal spray or sodium cromo-
glycate ophthalmic solution.
The study drugs were BIL 20 and 10 mg (BIL 20 and BIL 10,
respectively), fexofenadine hydrochloride 60 mg (FEX, Allegra®
60 mg tablet, Sanoﬁ, Tokyo, Japan), and the placebo. Because FEX
needs to be orally administered twice daily as the recommended
dose in Japan, it was administered twice daily while the placebo
was administered as the second dose in groups other than the FEX-
treated.
Tomaintain the blindness, the study drugs were encapsulated in
opaque oral capsules to ensure the contents were indistinguishable
and were randomly assigned to subjects by using a set assignment
order. The encapsulated study drugs were supplied by Taiho
Pharmaceutical.
The subjects were assessed for nasal symptoms (rhinorrhea,
sneezing, and nasal obstruction and itching) and ocular symptoms
(itchy eyes and ocular tearing) using a 5-point scale (0, no symp-
toms; 1, mild; 2, slightly severe; 3, severe; and 4, very severe). This
assessment method was used in our validation and clinical stud-
ies.6e8 During the pollen exposure, the subjects self-assessed their
nasal and ocular symptoms every 15 min.
The TNSS, total ocular symptom score (TOSS), and total symp-
tom score (TSS) were presented as the sum of the scores of four
nasal, two ocular, and a combination of four nasal and two ocular
symptoms, respectively. In addition, the number of sneezes was
recorded every 15 min during the exposure. Furthermore, the
subjects blew their noses with pre-weighed tissue papers, which
were subsequently weighed and the difference in weight beforeand after was recorded as the nasal secretion. No carry-over effect
was anticipated because we allowed for a sufﬁcient washout in-
terval between the treatment periods.Efﬁcacy evaluation
The primary objective was to compare the efﬁcacy of BIL against
that of the placebo during the treatment period. The primary
endpoint was the sum of TNSS at 0e3 h after the ﬁrst study drug
administration (Day 1).
The secondary efﬁcacy endpoints were the sum of TNSS and
nasal and ocular symptoms 22e26 h after the ﬁrst study drug
dosing (Day 2), and the onset of action on TNSS and nasal symp-
toms, whichwas deﬁned as the time point when the ﬁrst signiﬁcant
difference from placebo was observed.4 The subjects comprehen-
sively assessed the severity of symptoms using a 10-cm visual
analog scale (VAS), and the level of treatment satisfaction such as
efﬁcacy and safety at the end of the exposure Day 2 of each period
compared with that at the end of the screening exposure. The 5-
point scale used for this assessment was as follows; 1, very
dissatisﬁed; 2, dissatisﬁed; 3, normal; 4, satisﬁed; and 5, very
satisﬁed. The nasal secretion was examined every 60 min after the
start of exposure as well as the doseeresponse of BIL.Evaluation of safety
All the signs, symptoms, and disorders observed in the subjects
were considered adverse events (AEs), and the safety was evaluated
Table 1
Subject demographic and characteristics at baseline in per protocol set
(PPS).
Variable PPS population (n ¼ 126)
Sex n (%)
Female subjects 82 (65.1%)
Male subjects 44 (34.9%)
Age (years)
Mean ± SD 40.7 ± 10.6
Range 20e59
BMI (kg/m2)
Mean ± SD 21.65 ± 3.20
Range 15.8e31.2
Sum of TNSS75e240 min at screening
Mean ± SD 65.1 ± 23.2
Range 36e157
Sum of TOSS75e240 min at screening
Mean ± SD 17.8 ± 17.7
Range 0e91
Sum of TSS75e240 min at screening
Mean ± SD 82.9 ± 36.8
Range 36e248
Sum of amount of nasal secretion at screening (g)
Mean ± SD 12.20 ± 10.17
Range 2.1e48.2
Serum levels of JC pollen-IgE
Class 0 0 (0.0)
Class 1 0 (0.0)
Class 2 7 (5.6)
Class 3 42 (33.3)
Class 4 52 (41.3)
Class 5 13 (10.3)
Class 6 12 (9.5)
BMI, body mass index; IgE, immunoglobulin E; JC, Japanese Cedar; SD,
standard deviation; TNSS, total nasal symptom score; TOSS, total ocular
symptom score; TSS, total symptom score.
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and the 12-lead electrocardiogram (ECG).
Statistical analysis
The objective of this study was to detect a difference in the
primary efﬁcacy endpoint between BIL 20 and placebo for per
protocol set (PPS) population. The full analysis set (FAS) included all
randomized subjects who completed the study without protocol
deviations or violations of the inclusion, exhibiting exclusion
criteria, and who had a baseline and 13 assessments of the primary
efﬁcacy endpoint and received, at least, one dose of the study
medication. The PPS included all the FAS subjects who completed
the study without major protocol violations or deviations from the
main efﬁcacy and safety variables, as well as the administration
regimen. The safety population (SP) included all randomized sub-
jects who had received at least one dose of the study medication.
For the primary efﬁcacy endpoint, 108 subjects were required
for a power of 90% at a two-sided signiﬁcance level of 5% to detect a
20-point difference between BIL 20 and placebo in TNSS with a
standard deviation (SD) of 45, based on a previous overseas study.18
Assuming that approximately 20% of the PPS population might
withdraw from this study, 130 subjects were required.
For the primary efﬁcacy endpoint, the four-period crossover
study was analyzed using a linear mixed effect model with the PPS
population. The model had baseline, treatment, sequence, and
period as the ﬁxed effects and a random intercept for each subject.
Similar analyses were carried out on both the main efﬁcacy vari-
ables and the primary efﬁcacy endpoint. In addition, supportive
analyses for the FAS population were included.
When the superiority of BIL 20 over placebo was conﬁrmed for
the primary and secondary endpoints, the efﬁcacy of BIL was
exploratively examined against that of FEX. The onset of action,
nasal secretion, and VASwere analyzed by using a pairwise Student
t-test. For subject's satisfaction with the treatment, the results of
those with a score of 4 or 5 were summarized, and an intergroup
comparison was performed using Fisher's exact test.
The safety analyses were performed on the SP data while the
qualitative and quantitative variables were summarized using a
frequency distribution and the mean ± SD or standard error (SE)
and 95% conﬁdence interval (95% CI), respectively.
All the statistical analyses were performed using the statistical
analysis software (SAS) version 9.2 (SAS Institute, Cary, NC, USA). All
reported P-values were two-sided, and a P < 0.05 was considered
statistically signiﬁcant. The statistical analysis was conducted at
Mediscience Planning Inc., (Tokyo, Japan).
Ethical approval and clinical trial registration
This study was conducted in the OHIO Chamber managed by the
Tokyo Research Center of Clinical Pharmacology, according to the
Good Clinical Practice (GCP) and Declaration of Helsinki guidelines.
The protocol and informed consent were reviewed and approved
by the Institutional Review Board of Shinanozaka Clinic. All the
subjects submitted written informed consent before the start of the
study, which was registered at the Japan Pharmaceutical Informa-
tion Center (JAPIC, JapicCTI-132213).
Results
Subjects
Of the 391 subjects who submitted informed consent, 136 were
randomly assigned to the treatment groups in the treatment
period. Most dropout subjects did not meet the inclusion criteriaduring the screening exposure, or they exhibited any of the exclu-
sion criteria.
All the 136 subjects assigned to the treatment groups were
included in the SP and FAS while 126 of themwere included in the
PPS for the efﬁcacy evaluation. Ten subjects were excluded from the
PPS, out of which nine had missing efﬁcacy data on Day 1 and 2
including discontinuation (ﬁve subjects), and medication time
noncompliance was noted for one subject. Table 1 shows the sub-
ject demographics and characteristics at baseline in the PPS.
Efﬁcacy
Primary endpoint: sum of TNSS on Day 1
The mean ± SD of the sum of TNSS 0e3 h after administration of
the study drugs on Day 1 for the BIL 20, BIL 10, FEX, and placebowas
67.7 ± 28.4, 69.7 ± 26.7, 73.3 ± 26.0, and 85.0 ± 31.1, respectively.
The estimated mean of the difference in the sum of TNSS between
BIL 20 and placebo was 16.2 (95% CI, 12.3e20.1), showing a signif-
icant difference compared with placebo (P < 0.001, Table 2A).
Similarly, the signiﬁcant differences in the sum of TNSS between BIL
10 or FEX and placebo were 14.5 (10.7e18.4) and 12.0 (8.1e15.8),
respectively (P < 0.001). When the effect of BIL 20 on the sum of
TNSS was exploratory compared to that of FEX, the difference was
4.2 (0.4e8.1), which was signiﬁcant (P ¼ 0.032; Table 2A). Alter-
natively, no signiﬁcant difference existed between BIL 10 and FEX
while the results of the FAS were similar to those of the PPS (data
not shown).
Sum of TNSS on Day 2
The mean ± SD of the sum of TNSS 22e26 h after the admin-
istration of BIL 20, BIL 10, FEX, and placebo was 84.4 ± 33.0,
82.8 ± 34.0, 84.6 ± 36.3, and 109.5 ± 41.6, respectively. The
Table 2
Sum of total nasal symptom score (TNSS) in per protocol set (PPS).
Day 1 Placebo (n ¼ 126) Bilastine 10 mg (n ¼ 126) Bilastine 20 mg (n ¼ 126) Fexofenadine (n ¼ 126)
(A) Primary efﬁcacy endpoint: sum of TNSS at 0e3 h after ﬁrst study drug dosing on Day 1
Mean ± SD 85.0 ± 31.1 69.7 ± 26.7 67.7 ± 28.4 73.3 ± 26.0
Estimated 84.7 70.2 68.5 72.7
Difference (95% CI) e 14.5 (10.7e18.4) 16.2 (12.3e20.1) 12.0 (8.1e15.8)
P-value* e <0.001 <0.001 <0.001
Difference (95% CI) e 2.6 (1.3e6.4) 4.2 (0.4e8.1) e
P-value** e 0.194 0.032 e
Difference (95% CI) e 1.7 (2.2e5.5) e
P-value*** e 0.395 e
Day 2 Placebo (n ¼ 126) Bilastine 10 mg (n ¼ 126) Bilastine 20 mg (n ¼ 126) Fexofenadine (n ¼ 126)
(B) Secondary efﬁcacy endpoint: sum of TNSS at 22e26 h after ﬁrst study drug on Day 2
Mean ± SD 109.5 ± 41.6 82.8 ± 34.0 84.4 ± 33.0 84.6 ± 36.3
Estimated 109.5 83.1 85.0 84.2
Difference (95% CI) e 26.4 (20.4e32.4) 24.5 (18.5e30.5) 25.3 (19.4e31.3)
P-value* e <0.001 <0.001 <0.001
Difference (95% CI) e 1.1 (4.9e7.0) 0.8 (6.8e5.2) e
P-value** e 0.730 0.789 e
Difference (95% CI) e 1.9 (7.9e4.1) e
P-value*** e 0.540 e
Analysis of a linear mixed effect model with the PPS population. Model had baseline, treatment, sequence and period as ﬁxed effects and a random intercept for each subject. *
vs. placebo, ** vs. fexofenadine, and *** vs. bilastine 10 mg.
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BIL 10, and FEX was 24.5 (18.5e30.5), 26.4 (20.4e32.4), and 25.3
(19.4e31.3), respectively, and all the active drugs showed a signif-
icant difference compared with placebo (P < 0.001, Table 2B).
Moreover, there was no signiﬁcant difference between the drugs.Sum of TOSS, TSS, total 3 nasal symptom score (T3NSS), and
individual symptom scores on Day 1 and 2
All the active drugs showed a signiﬁcant difference compared to
placebo in the sum of TOSS, total 3 nasal symptom score (T3NSS:
rhinorrhea, sneezing, and nasal itching), TSS, and for each nasal or
ocular symptom (rhinorrhea, sneezing, nasal obstruction, nasal
itching, itchy eyes, and ocular tearing) on Day 1 and 2 using a
mixed-effects model (P  0.001 each, Supplementary Table 1).
The exploratory comparison of the efﬁcacy of the above vari-
ables between BIL and FEX revealed a signiﬁcant improvement in
the sum of T3NSS and sneezing score for BIL 20 on Day 1 (P ¼ 0.036
and 0.011, respectively) and itchy eyes for BIL 10 on Day 2
(P ¼ 0.044) was observed (Supplementary Table 1).Doseeresponse relationship
There was no statistically signiﬁcant difference in any of the
efﬁcacy variables in the direct comparison of BIL 20 and BIL 10. In
addition, the doseeresponse of BIL on primary and secondary ef-
ﬁcacy endpoints was exploratory investigated by using the contrast
test using contrast coefﬁcients (1, 0, 1), (2, 1, 1), and (1, 1, 2)
for the treatment groups (placebo, BIL 10, and BIL 20), and no clear
doseeresponse relationship was observed (data not shown).Fig. 2. Time course of total nasal symptom score (TNSS) assessed every 15 min during
pollen exposure on Day 1 and 2 in per protocol set (PPS). Data are mean ± standard
error (SE, n ¼ 126). Subjects were exposed to JC pollen for 4 h; ﬁrst study drug was
orally administered 1 h after start of exposure. Second study drug was administered
12 h after ﬁrst drug dose. On Day 2, subjects returned to OHIO Chamber 22 h after ﬁrst
dose and were further exposed to JC pollen for 4 h. Statistical analyses are shown in
Supplementary Table 2. JC, Japanese cedar.Onset of action and duration
The time-course of the mean TNSS after pollen exposure is
shown in Figure 2 and values for BIL 20, BIL 10, FEX, and placebo
before pollen exposure on Day 1 were 2.6 ± 2.48, 2.7 ± 2.03,
2.5 ± 2.37, and 2.6 ± 2.36, respectively. After the start of pollen
exposure, the TNSS of each group rapidly increased time-
dependently. The TNSS at baseline (just before the ﬁrst study
drug dosing) was 6.4 ± 2.8, 6.5 ± 2.9, 6.6 ± 2.8, and 6.6 ± 2.8 for BIL
20, BIL 10, FEX and placebo, respectively. There was no signiﬁcant
difference between the drugs before pollen exposure and at
baseline.After administration of placebo, the mean TNSS was maintained
at 6e7 points during the pollen exposure on Day 1 and then it
gradually decreased until the start of the second pollen exposure
(at 22 h), after which it rapidly increased and reached a plateau 1 h
after the second pollen exposure on Day 2.
A signiﬁcant decrease in TNSS following the active drug treat-
ments was observed from approximately 1 h and was maintained
for up to 26 h after the ﬁrst drug dosing compared with placebo
(Fig. 2, and Supplementary Table 2). The onset of action for TNSSwas
45min for BIL 20 (versus [vs.] placebo, P¼ 0.019), and 60min for BIL
10 and FEX (vs. placebo, P ¼ 0.002 and P ¼ 0.037, respectively,
Table 3 and Supplementary Table 2). All the active drugs signiﬁ-
cantly suppressed the increase in TNSS for up to 26 h after the ﬁrst
drug dose compared to placebo (Fig. 2 and Supplementary Table 2).
Figure 3 shows the time-course of each mean nasal symptom
score (rhinorrhea, sneezing, nasal obstruction, and nasal itching)
after pollen exposure on Day 1 and 2. The change in each nasal
symptom score showed a similar patternwith that of the TNSS. The
rhinorrhea, nasal obstruction, and itching score were the main
components of TNSS based on the comparison with the change in
mean score after pollen exposure. The mean nasal symptom scores
Table 3
Onset of action for total nasal symptom score (TNSS) and each nasal symptom score
in per protocol set (PPS).
(min) TNSS
(n ¼ 126)
Rhinorrhea
(n ¼ 126)
Sneezing
(n ¼ 126)
Nasal
obstruction
(n ¼ 126)
Nasal itching
(n ¼ 126)
Bilastine
10 mg
60 60 60 105 60
Bilastine
20 mg
45 60 45 60 60
Fexofenadine 60 75 60 180 75
Onset of action was ﬁrst time point after ﬁrst study drug dosing when drug
demonstrated a signiﬁcant difference from placebo (Student t-test).
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the active drugs signiﬁcantly decreased each nasal symptom on
Day 1 and 2 compared with placebo, similar to their effects on the
TNSS (Supplementary Table 2). The onset of action for BIL 20 on
each nasal symptomwaswithin 60min. Compared with FEX, BIL 20
had a rapid onset of action against all the nasal symptoms (Table 3).Symptom severity using 10-cm VAS
The mean change in the VAS from baseline every 1 h during the
4-h pollen exposure is shown in Figure 4. Themean ± SD of the VAS
at baseline for BIL 20, BIL 10, FEX, and placebo was 39.6 ± 21.1,
40.5 ± 20.5, 41.3 ± 20.6, and 42.3 ± 21.3, respectively. Themean VAS
of the placebo group was not largely changed from the baseline
during pollen exposure on Day 1, and it partly decreased before theFig. 3. Time course of nasal symptoms. (A) Rhinorrhea, (B) sneezing, (C) nasal obstruction, a
per protocol set (PPS). Data are mean ± standard error (SE, n ¼ 126). Procedures of exposure
Supplementary Table 2. JC, Japanese cedar.second pollen exposure (at 22 h), after which it increase during the
second pollen exposure on Day 2. On the other hand, the VAS of the
active drugs decreased and increased time-dependently on Day 1
and 2, respectively. The change in the VAS from the baseline for BIL
20 was more signiﬁcantly decreased than that of placebo from 1 to
26 h after the ﬁrst drug dose, except at 22 h. The BIL 10 and FEX also
signiﬁcantly improved the VAS from 2 to 26 h after the ﬁrst drug
dose (except at 22 h for BIL 10) compared with placebo. There was
no signiﬁcant difference between the active drugs.
Nasal secretion
Figure 5 shows the mean nasal secretion every 1 h during the
pollen exposure, and all the active drugs showed a signiﬁcant
attenuation from 2 to 26 h after the ﬁrst drug dose compared to
placebo. There was no signiﬁcant difference between the active
drugs.
Subject treatment satisfaction
The percentage (ratio) of subjects who responded that they
were satisﬁed or very satisﬁed with the treatment was 44.4% (56/
126), 41.3% (52/126), 40.5% (51/126), and 14.3% (18/126) for BIL 20,
BIL 10, FEX, and placebo, respectively. All the active drugs showed a
signiﬁcant difference compared with placebo (P < 0.001 each).
Safety
No serious AEswere reported in this studywhile AEs occurred in
31 subjects, which consisted of eight subjects each in the BIL 10, BILnd (D) nasal itching assessed every 15 min during JC pollen exposure on Day 1 and 2 in
and study drug administration are same as for Figure 2. Statistical analyses are shown in
Fig. 4. Change in visual analog scale (VAS) score from baseline every 1 h during Japanese cedar (JC) pollen exposure on Day 1 and 2 in per protocol set (PPS). Data are
mean ± standard error (SE, n ¼ 126). *P < 0.05, ***P < 0.001 for bilastine (BIL) or fexofenadine (FEX) versus placebo (Student's t-test). EEC, environmental exposure chamber; VAS,
visual analog scale. No signiﬁcant difference observed between active drugs (Student's t-test).
Fig. 5. Amount of nasal secretion every hour during Japanese cedar (JC) pollen exposure on Day 1 and 2 in per protocol set (PPS). Data are mean ± standard error (SE, n ¼ 126).
**P < 0.01 and ***P < 0.001 for bilastine (BIL) or fexofenadine (FEX) versus placebo (Student's t-test). No signiﬁcant difference observed between active drugs (Student's t-test).
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(one subject in the BIL 10) and abnormal liver function test, head-
ache, and somnolence (in one subject each in the FEX group) were
determined to be adverse drug reaction (ADRs). However, they
were all mild and clinically insigniﬁcant. One subject (BIL 10
treatment, Period 2) who reported nasopharyngitis was withdrawn
from the study. The investigator considered this AE to have been
caused by a transient infection and was deemed unrelated to study
drug.
Discussion
The aim of this study was to compare the efﬁcacy of therapeutic
treatment with BIL and placebo, and to assess the onset and
duration of action of BIL on JC pollinosis symptoms in Japanese
subjects exposed JC pollen using the OHIO Chamber. Therefore, we
adopted a study design that incorporated a consecutive 3-day (Day
1, Day 1 and Day 2) JC pollen exposure in the present study
(Fig. 1B). The 2-h JC pollen exposure on Day 1 was performed to
induce a priming effect. Yuki A et al.19 reported that with the 3-
consecutive-day challenge (50,000 grains/mm3 for 2 h), the
severity of symptoms was seen to increase proportionally with the
number of days of challenge in patients with JC pollinosis. In
addition, 1-h priming pollen exposure (8000 grains/mm3) of the
previous day increased the sensitivity of the nasal mucosa and
subsequent 3-h exposure induced more severe allergic symptoms
on the next day in patients with JC pollinosis.20 We examined the
effect of a 2-h priming JC pollen exposure on the development ofnasal symptoms following consecutive JC pollen exposure in sub-
jects with JC pollinosis before the conduct of this study. As the re-
sults, we obtained the same results indicating that the priming 2-h
exposure facilitated the occurrence of the nasal symptoms, and
increased the nasal symptom score following pollen exposure on
Day 1 (unpublished data). To investigate the efﬁcacy, onset, and
duration of action of BIL, the JC pollen exposure was performed for
4 h on Day 1 and 2, followed by the oral administration of the study
drug 1 h after the pollen exposure on Day 1. Moreover, to compare
the efﬁcacies of BIL and FEX, FEX or placebo was re-administered
orally 12 h after the ﬁrst drug dose (approximately 10 h before
the pollen exposure on Day 2). The duration of pollen exposure and
timing of the ﬁrst study drug dosing was determined for the
following reasons. (i) The TNSS achieved a plateau 90e120 min
after the start of the exposure during our initial experience in the
implementation of the EEC studies without the priming
exposure.6e8 (ii) The manifestation of the nasal symptoms on Day 1
could be prompted to occur earlier by performing the priming
exposure on Day 1. (iii) The onset of action of BIL and FEX was
expected to occur approximately 60 min after dosing.18,21 (iv) The
efﬁcacy assessment of study drugs has usually been performed
following a 3-h pollen exposure in our previous EEC studies.9,10,13
(v) In addition, to ensure the completion of the study by the sub-
jects, we needed tomitigate the associated inconveniences as much
as possible.
The results of the present study clearly demonstrated that
treatment with a single 10 or 20 mg dose of BIL signiﬁcantly sup-
pressed the sum of TNSS at 0e3 h, as well as the sum of TNSS at
K. Hashiguchi et al. / Allergology International 66 (2017) 123e13113022e26 h after the ﬁrst dose compared with placebo (Table 2). In
addition, both BIL 10 and BIL 20 improved the sum of TOSS, T3NSS,
TSS, each nasal or ocular symptom score, the VAS, and nasal
secretion on Day 1 and 2 compared with placebo (Fig. 3e5).
FEX was orally administered twice a day according to the Jap-
anese dose regimen in the present study. Therefore, the therapeutic
effects and onset of action of FEX on Day 1 following the admin-
istration of a single 60 mg dose, and its duration of action on Day 2
twice daily dosing with 60 mg were investigated. The results
revealed that FEX also suppressed the sum of TNSS, TOSS, T3NSS,
TSS, each nasal or ocular symptom score, the VAS, and nasal
secretion on Day 1 and 2, similar to BIL. Furthermore, there was no
signiﬁcant difference in the sum of TNSS on Day 2 among the active
drugs (Table 2B). The changes in TNSS, each nasal symptom score,
the VAS, and nasal secretion also showed a similar tendency with
the active drugs on Day 2 (Fig. 2e5), suggesting that the duration of
action of a single 10 or 20 mg dose of BIL was comparable to that of
a twice daily 60 mg dose of FEX. On the other hand, the following
differences were observed in the inhibitory effects of BIL and FEX.
(i) The inhibitory effect of BIL 20 on the sum of TNSS, T3NSS, and
sneezing score on Day 1 was signiﬁcantly greater than that of FEX.
(ii) The sum of itchy eye score of BIL 10 on Day 2 was more
signiﬁcantly decreased than that of FEX. (iii) The onset of action for
TNSS and each nasal symptom score of BIL 10, BIL 20, and FEX was
60e105, 45e60, and 65e180 min, respectively. These results sug-
gest that the inhibitory effect of BIL 20 was relatively greater than
that of FEX was, and the onset of action of BIL 20 was faster than
that of FEX and BIL 10. Furthermore, these results were consistent
with that of a previous study, which reported that the antihista-
mine activity of a single dose of BIL 20 was faster than that of BIL 10
in the histamine prick test in healthy Japanese subjects (submitted
for publication).
This study did not entirely clarify if the complete doseeresponse
of BIL is within the dose range of 10e20 mg. However, BIL 20
showed a faster onset of action than BIL 10 or FEX did, and the sum
of T3NSS and sneezing scores of BIL 20 on Day 1 were signiﬁcantly
lower than those of FEX but not BIL 10 were. Therefore, it could be
concluded that BIL 20 is more clinical usefulness than BIL 10 is, and
should be selected as the candidate dose level for pivotal studies in
patients with allergic rhinitis. All the medications investigated
were safe and well tolerated in this study population.
Our results were consistent with those of a previous overseas
EEC study,18 which reported that BIL 20 had a rapid onset of action
and a long duration of action (1 h and greater than 26 h, respec-
tively). Some differences were observed between the study design
of this present study and that of the overseas study. These differ-
ences were in the pollen type used (this study vs. the overseas, JC
vs. glass pollen), the duration of exposure (Day 1 and 2, 4 h each vs.
Day 1 and 2, 6 and 4 h, respectively), the study drug administration
time (1 vs. 2 h after the start of exposure), and the study drug
dosing times (twice vs. once). The mean of the sum of TNSS in the
overseas study was higher than that of this study; however,
compared to the placebo, the percentage reduction of BIL 20 on Day
1 and 2 was 20.4 and 22.9% (this study) vs. 16.7 and 21.8%
(overseas study). This comparison indicates that the efﬁcacy of BIL
20 on the JC pollinosis was comparable to its effects on grass pollen
allergy in Caucasians subjects.
This study has some limitations, which are worth mentioning.
(i) This EEC study may have resulted in the short duration, the
restricted study design and the manner of execution. The onset of
action of the active drugs appeared shorter than that observed in
phase III trials conducted during the pollen season.4 Therefore, it
would be necessary to assess the onset of action of BIL in phase III
trials that reﬂect the real life setting. (ii) We set the priming
exposure on Day 1 to induce the priming effect. However, thepriming effects in this study may differ from those obtainable in a
natural environment. The reactivity of patients to the JC allergen
could have been increased by repeated low-level JC pollen exposure
before the start of JC pollen dispersal, which would induce the
priming effect.22 In fact, the pollen dispersal concentration
(8000 grains/m3) in the chamber, which is comparable to that
obtainable when a large quantity of JC pollen is dispersed, was
needed to elicit the mild to moderate nasal symptoms in our EEC
studies.8 Therefore, differences in the pathophysiological charac-
teristic may have existed between the EEC and natural environ-
ment study after the priming effect. (iii) Based on the protocol used,
the duration of this study was relatively short and, therefore, it may
not be suited nor intended to explore extended long-term efﬁcacy
or safety of BIL.
Since it is important to predict the efﬁcacy or doseeresponse of
new medications prior to conducting the pivotal study in patients
with allergic rhinitis, it might be worth considering using the EEC
study to evaluate the efﬁcacy and doseeresponse of therapeutic or
prophylactic treatment with the new medication in Japanese sub-
jects with JC pollinosis. The study design used in the present study
might be useful for conducting therapeutic studies using the EEC
study in Japanese subjects with JC pollinosis.
In conclusion, this study demonstrated the clinical usefulness of
BIL 20 for the treatment of JC pollinosis. Furthermore, BIL 20
showed a rapid onset and long duration of action against nasal
symptoms induced by the 3-day consecutive exposure to JC pollen
in the OHIO Chamber.
Acknowledgments
The authors gratefully acknowledge Drs. Lourdes Azcarate,
Roman Valiente, and Luis Labeaga (Faes Farma S.A., Spain) for their
scientiﬁc review of the manuscript. The authors would also like to
thank Satoko Shimizu and all the members who participated in this
study at the Tokyo Research Center of Clinical Pharmacology for the
construction of the OHIO Chamber as well as managing and coor-
dinating the tests and subject's visiting schedule. We would also
like to thank Keika Tsuruya and Yusuke Iida (Taiho Pharmaceutical)
who played an overall management role in the study. This study
was funded by Taiho Pharmaceutical, Tokyo, Japan.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.alit.2016.06.009.
Conﬂict of interest
MT, AS are employees of Taiho Pharmaceutical. KO received adviser fees from
Taiho Pharmaceutical. The rest of the authors have no conﬂict of interest.
Authors' contributions
KH, the principal investigator, contributed to the conduct of the study, as well as
data collection and interpretation. KW contributed to the conduct of the study and
data collection. MT, AS contributed to the study concept, design, and conduct, as well
as data analysis and interpretation. KH, MT, AS wrote the manuscript. KO, a medical
adviser, provided advice on the study design and conduct, as well as data inter-
pretation. All the listed authors were involved in the critical review and revision of
the manuscript and approved the ﬁnal content.
References
1. Okubo K, Kurono Y, Fujieda S, Ogino S, Uchio E, Odajima H, et al. Japanese
guideline for allergic rhinitis 2014. Allergol Int 2014;63:357e75.
2. Day JH, Horak F, Briscoe MP, Canonicaz GW, Fineman SM, Krug N, et al. The role
of allergen challenge chambers in the evaluation of anti-allergic medication: an
international consensus paper. Clin Exp Allergy Rev 2006;6:31e59.
3. Krug N, Badorrek P, Hohlfeld JM. Experience with an allergen challenge
chamber for clinical trials in allergic rhinitis. Clin Exp Allergy Rev 2012;12:14e9.
K. Hashiguchi et al. / Allergology International 66 (2017) 123e131 1314. U.S. Department of Health and Human Services, Food and Drug Administration,
Center for Drug Evaluation and Research. Allergic Rhinitis: Clinical Development
Programs for Drug Products. DRAFT GUIDANCE. 2000.
5. Committee for Medicinal Products for Human Use, European Medicines
Agency. Guideline on the Clinical Development of Medicinal Products for the
Treatment of Allergic Rhinoconjunctivitis. EMEA/EWP/2455/02. 2004.
6. Hashiguchi K, Tang H, Fujita T, Tsubaki S, Fujita M, Suematsu K, et al. Pre-
liminary study on Japanese cedar pollinosis in an artiﬁcial exposure chamber
(OHIO Chamber). Allergol Int 2007;56:125e30.
7. Hashiguchi K, Tang H, Fujita T, Suematsu K, Tsubaki S, Nagakura H, et al. Pilot
study of Japanese cedar pollen exposure using a novel artiﬁcial exposure
chamber (OHIO Chamber). Clin Exp Allergy Rev 2008;8:30e6.
8. Hashiguchi K, Tang H, Fujita T, Suematsu K, Tsubaki S, Nagakura H, et al.
Validation study of the OHIO Chamber in patients with Japanese cedar polli-
nosis. Int Arch Allergy Immunol 2009;149:141e9.
9. Hashiguchi K, Tang H, Fujita T, Suematsu K, Gotoh M, Okubo K. Bepotastine
besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen
exposure in an artiﬁcial exposure chamber (OHIO Chamber). Expert Opin
Pharmacother 2009;10:523e9.
10. Wakabayashi K, Hashiguchi K, Kanzaki S, Fujioka M, Tanaka N, Kawashima K,
et al. Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in
children using OHIO chamber. Allergy Asthma Proc 2012;33:102e9.
11. Enomoto T, Ide T, Ogino S. Construction of an environmental exposure unit and
investigation of the effects of cetirizine hydrochloride on symptoms of cedar
pollinosis in Japan. J Investig Allergol Clin Immunol 2007;17:173e81.
12. Yamamoto H, Yonekura S, Sakurai D, Katada K, Inamine A, Hanazawa T, et al.
Comparison of nasal steroid with antihistamine in prophylactic treatment
against pollinosis using an environmental challenge chamber. Allergy Asthma
Proc 2012;33:397e403.
13. Kanzaki A, Hashiguchi K, Takeshi M, Tsurumi M, Okubo K, Ogawa K. [Artiﬁcial
exposure chamber (OHIO) trial: inhibitory effect of bepotastine-OD for nasal
allergy III (ACTION III study)]. [ J New Rem Clin] 2012;61:2208e15 (in Japanese).14. North ML, Soliman M, Walker T, Steacy LM, Ellis AK. Controlled allergen
challenge facilities and their unique contributions to allergic rhinitis research.
Curr Allergy Asthma Rep 2015;15:11.
15. Ilaxten 20 mg Tablets. Bilastine 20 mg. Summary of Product Characteristics.
Available at URL: http://www.mhra.gov.uk/spc-pil/?prodName¼ILAXTEN20MG
TABLETS&subs Name ¼&pageID¼ThirdLevel&searchTerm¼bilastine#retain
Display [accessed 27.11.15].
16. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, et al.
Efﬁcacy and safety of bilastine 20 mg compared with cetirizine 10 mg and
placebo for the symptomatic treatment of seasonal allergic rhinitis: a ran-
domized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:
1338e47.
17. Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, et al. Comparison
of the efﬁcacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal
allergic rhinitis patients. Allergy 2009;64:158e65.
18. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine
compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal
and ocular symptoms in patients exposed to aeroallergen in the Vienna
Challenge Chamber. Inﬂamm Res 2010;59:391e8.
19. Yuki A, Terada T, Ichihara T, Fujii K, Hyo S, Kawata R, et al. Evaluating the effects
of testing period on pollinosis symptoms using an allergen challenge chamber.
Allergol Int 2011;60:533e9.
20. Yonekura S, Okamoto Y, Yamamoto H, Sakurai T, Iinuma T, Sakurai D, et al.
Randomized double-blind study of prophylactic treatment with an anti-
histamine for seasonal allergic rhinitis. Int Arch Allergy Immunol 2013;162:
71e8.
21. Day JH, Briscoe MP, Welsh A, Smith JN, Clark A, Ellis AK, et al. Onset of action,
efﬁcacy, and safety of a single dose of fexofenadine hydrochloride for ragweed
allergy using an environmental exposure unit. Ann Allergy Asthma Immunol
1997;79:533e40.
22. Connell JT. Quantitative intranasal pollen changes. III. The priming effect in
allergic rhinitis. J Allergy 1969;43:33e44.
